Previous 10 | Next 10 |
Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022. An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash. ...
Arbutus Biopharma (NASDAQ:ABUS) is trading ~4% higher in the pre-market Monday after H.C. Wainwright increased its price target, citing early data expected from three studies run by the clinical-stage biotech. The analyst Ed Arce also refers to the damages sought by the company from...
Despite being hot off $18.5 billion in revenue from sales of its coronavirus vaccine last year, Moderna (NASDAQ: MRNA) might just have trouble brewing. On Feb. 28, Arbutus Biopharma (NASDAQ: ABUS) initiated a lawsuit against Moderna, claiming that the company had infringed o...
Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022. Results from the phase 1a/1b study using AB-729 for Hep B from multiple cohorts are expected at a medical conference in 2022. Results from the ...
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q4 2021 Earnings Call Mar 03, 2022 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q4 2021 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q4 2021 Earnings Conference Call March 3, 2022, 8:45 AM ET Company Participants Lisa Caperelli - Vice President, Investor Relations William Collier - President and Chief Executive Officer David Hastings - Chief Financial Officer Gaston Picchio - Chief Deve...
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with their 2021 Q4 earnings call. For further details see: Arbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call Presentation
Arbutus Biopharma press release (NASDAQ:ABUS): FY GAAP EPS of -$0.83 beats by $0.03. Revenue of $11M (+59.2% Y/Y) beats by $0.35M. Shares -0.3% PM. CEO comment: “We formed strategic and clinical partnerships that allowed us to explore several combination therapies with AB-729, our RNAi...
Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022 Expected to complete IND-enabling studies for two oral compounds (PD-L1 inhibitor AB-101 and RNA destabilizer AB-161) to treat HBV in the second half of 2022 Anticipate advan...
Arbutus Biopharma (NASDAQ:ABUS) is scheduled to announce Q4 earnings results on Thursday, Mar. 3, before market open. The consensus EPS estimate is -$0.20 and the consensus revenue estimate is $2.87M. Over the last 2 years, ABUS has beaten EPS estimates 38% of the time and has beaten revenue ...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...